As the fourth most common cause of hospital-acquired bloodstream infections in the United States, Invasive Candidiasis is a concern for any patient battling a fungal infection. Micafungin, also known as the brand name Mycamine, which is marketed by Astellas, is an effective antifungal agent. By inhibiting the synthesis of 1,3-beta-D-glucan, Micafungin proves to be a[…]
Micafungin Remains a Viable Treatment for Candida Infections
Anti-Fungal, Drug Research & Development API, FDA Approved 2013 Tags: United States Apr 08, 2015
Pomalidomide Shines at the American Society of Hematology Annual Meeting
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, FDA Approved 2013, Immunological Agent Tags: multiple myeloma Feb 17, 2015
Impressive news dominated the headlines at the 56th American Society of Hematology annual meeting regarding anti-cancer powerhouse Pomalidomide. Results from a comprehensive study conducted by Celgene Corporation, the company that markets the brand name of Pomalidomide, POMALYST, were extremely encouraging. The trial, coined STRATUS, involved 599 patients suffering from refractory or relapsed multiple myeloma. Patients[…]
FDA Approves Unique Multimodal Vortioxetine for Major Depressive Disorder
Antidepressant, FDA Approved 2013 Tags: Major Depressive DisorderserotoninSSRI Oct 07, 2013
The approval of Vortioxetine CAS# 508233-74-7 came as exciting news at the close of September 2013. Known as the brand name Brintellix, Vortioxetine is marketed by Lundbeck and Takeda Pharmaceuticals. The FDA approval of this antidepressant is encouraging for both patients suffering from Major Depressive Disorder and the practitioners who treat these patients, as Vortioxetine[…]
Canagliflozin FDA Approved For Type 2 Diabetes
Anti-Diabetic, FDA Approval News, FDA Approved 2013 Tags: canagliflozintype 2 Diabetes Mar 29, 2013
Canagliflozin FDA approved as a new and unique treatment for type 2 diabetes. There were nine clinical trials involving more than 10,285 patients with type 2 diabetes. The trials showed positive results with greater glycemic control in patients. The recommended use for Canagliflozin patients includes a strict regimen of diet and exercise. The drug also outperforms similar[…]
A New Regorafenib FDA Approval for GIST Patients
Chemotherapeutic / Anti-Neoplastic, FDA Approved 2013 Tags: imatinibregorafenib Mar 01, 2013
Bayer announced the Regorafenib FDA Approval on February 25, 2013. Known as the brand name Stivarga, Regorafenib is specifically for patients with gastrointestinal stromal tumor (GIST) that is unresectable. Regorafenib is a last option treatment for patients with GIST who have metastatic cancer that is unresponsive to first line treatments approved by the FDA, like[…]
